The AIDA Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, designed for the functional disruption of the AIDA gene (Axin interactor, dorsalization-associated). This polyclonal knockout model provides a heterogeneous pool of gene-edited cells, eliminating the need for single-cell cloning and accelerating experimental workflows. By leveraging CRISPR/Cas9-mediated targeting, the product introduces loss-of-function mutations across the cell population, enabling robust studies of AIDA-dependent signaling networks without the confounding effects of clonal selection.
A-549 cells, established from the lung tissue of a 58-year-old male with adenocarcinoma, serve as a widely adopted model of human alveolar Type II epithelium. These cells exhibit characteristic epithelial morphology and retain key signaling pathways relevant to lung cancer biology, including active Wnt/??-catenin and mitogen-activated protein kinase (MAPK) cascades. Their suitability for transfection, viral transduction, and high-throughput screening makes them an ideal host for generating knockout models aimed at dissecting oncogenic mechanisms in non-small cell lung cancer (NSCLC).
AIDA functions as a critical modulator of Wnt/??-catenin signaling by binding AXIN1 and disrupting its homodimerization, thereby impeding the ??-catenin destruction complex (comprising AXIN1, GSK3B, and APC) and leading to stabilization and nuclear accumulation of CTNNB1 (??-catenin). This, in turn, promotes transcription of Wnt target genes via TCF7/LEF transcription factors. Independently, AIDA scaffolds AXIN1 and TAB1 to suppress the activation of MAP3K7 (TAK1), attenuating downstream JNK (MAPK8) and p38 (MAPK14) MAPK pathway activity, which influences JUN and FOS transcription factor responses. Thus, AIDA orchestrates crosstalk between Wnt and stress-activated MAPK pathways, with implications for cell proliferation, differentiation, and survival.
In the A-549 lung adenocarcinoma context, AIDA??s dual regulatory role positions it at the nexus of pathways frequently dysregulated in NSCLC, where aberrant Wnt activity and MAPK signaling drive tumor growth, metastasis, and resistance to therapy. The knockout of AIDA in this cell line allows researchers to dissect how loss of this scaffold protein alters pathway balance, potentially unveiling synthetic lethal interactions or biomarkers for Wnt- or MAPK-targeted interventions. The polyclonal nature of the knockout further mimics heterogeneous tumor cell populations, enhancing the translational relevance of findings.
Researchers can employ this knockout model to investigate Wnt/??-catenin-dependent transcriptional programs using TOP/FOP luciferase reporter assays and RT-qPCR for AXIN2 and CTNNB1, or to examine MAPK pathway perturbations through western blot analysis of phospho-JNK and phospho-p38. Functional studies, including cell proliferation, scratch migration, and apoptosis assays, alongside omics approaches such as RNA-seq, enable comprehensive phenotypic characterization. Additionally, these cells facilitate drug resistance studies by assessing response to Wnt inhibitors or MAPK antagonists. For detailed product information and ordering, please contact Ascent Research.
